Fourth Quarter & Full Year 2023 Financial Results and Business Update Conference Call

Patrick Holt
President & CEO

Tom Reilly
CFO



AMARIN®

February 29, 2024

Forward Looking Statements & Disclaimer

This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA® (VAZKEPA® in Europe), clinical and regulatory efforts and timelines, potential regulatory and pricing approvals, generic product launches, research and development, intellectual property and litigation matters, and other statements and beliefs that are forward-looking in nature and depend upon or refer to future events or conditions, including certain financial initiatives, metrics, and guidance.

These statements involve known and unknown risks, uncertainties and other factors that can cause actual results to differ materially. Investors should not place undue reliance on forward-looking statements, which speak only as of the presentation date of this presentation. Please refer to the "Risk Factors" section in Amarin's most recent Forms 10-K and 10-Q filed with the SEC and cautionary statements outlined in recent press releases for more complete descriptions of risks in an investment in Amarin.

THIS PRESENTATION IS INTENDED FOR COMMUNICATION WITH INVESTORS AND NOT FOR DRUG PROMOTION.

Today's Agenda

01

Fourth Quarter & Full-Year 2023 Business Highlights & 2024 Priorities
Patrick Holt, President & CEO

02

Fourth Quarter & Full-Year 2023 Financial Results
Tom Reilly, CFO

03

Q&A
Patrick Holt, President & CEO
Tom Reilly, CFO

01

FOURTH QUARTER & FULL YEAR 2023 BUSINESS HIGHLIGHTS AND 2024 PRIORITIES

Patrick Holt, President & CEO

OUR STRATEGY: FOCUS ON OPERATIONAL MOMENTUM TO MAXIMIZE PATIENT UPTAKE ON VASCEPA/VAZKEPA

EUROPE
Accelerate European Revenue and P&R Outcomes

U.S.
Extend Product Lifecycle and Drive Profit

RoW
Maximize Patient Uptake via Partnerships

2023 BUSINESS HIGHLIGHTS & 2024 PRIORITIES

EUROPE

2023:

- ✓ Delivered ~65% growth in Q4 vs Q3 '23 powered by Spain
- ✓ Secured pricing and reimbursement, launched VAZKEPA in 3 additional markets.

2024:

- Accelerate revenue in Europe in key launched markets including Spain and UK.
- Advance pricing and reimbursement processes in key markets including Italy, France, and Germany.

REST OF WORLD

2023:

- ✓ Secured 5 Rest of World regulatory approvals, including China (VHTG); advanced CVRR regulatory process in China
- ✓ Entered into agreements in key markets and regions, including Australia & New Zealand and ASEAN/South Korea.

2024:

- Support P&R, commercialization efforts across key markets, including Australia and China.
- Continue to progress Rest of World regulatory filings.

U.S.

2023:

- ✓ Continued to retain its IPE market share leadership in the U.S. at 57%, despite additional generic competition.

2024:

- Focus on maintaining IPE market share leadership and profitability while continuing to adapt to dynamic market conditions.

R&D/MEDICAL

2023:

- ✓ ~50 Additional Abstracts & Publications Supporting VASCEPA/VAZKEPA; 140 Educational Initiatives Executed Across Europe; Strong Presence at 5 Major Congresses

2024:

- Continue to advance REDUCE-IT, EPA data; 7 accepted abstracts at American College of Cardiology Meeting in April

02

FOURTH QUARTER & FULL YEAR 2023 FINANCIAL RESULTS

Tom Reilly, CFO

Q4/FY 2023 FINANCIAL RESULTS

Q4 '23 Total Revenue of $75M

- USA Net Revenue: $65 million
- European Revenue: $1.5 million; ~65% increase versus Q3 2023
- ROW Revenue: $8M (includes Edding Supply Shipments & Milestone Achievement)



2023 Operating Expenses

- $21M reduction in Total Operating Expenses 1H vs. 2H 2023
- On-track to deliver $40M reduction by July 2024 as announced in July 2023



CONTINUED FOCUS ON CONTROLLING COSTS AND MAXIMIZING CASH

Strong Cash Position; Six Consecutive Quarters of Positive/Neutral Cash Flow



Full Year 2023 Cash Position
Cash Flow Positive +$10M versus 12/31/22

- Cash Balance of $321M as of 12/31/23;
- Cash Flow Positive $10M for Full Year 2023
- 6 quarters of cash flow positive or neutral ops[1]
- Expense reductions and timely EUR investments based on pricing and reimbursement decisions
- Continued progress renegotiating supply purchase agreements - process ongoing

[1] Excludes one-time supply restructuring payments.

03 Q&A

Patrick Holt, President & CEO

Tom Reilly, CFO

Vascepa®
(icosapent ethyl)

Vazkepa®
(icosapent ethyl)

THANK YOU

AMARIN®